Marc Devocelle (https://www.rcsi.com/people/profile/mdevocelle) completed his PhD at the University of Lille (France) in the laboratory of Professor André Mortreux (homogeneous catalysis), under contract with the pharmaceutical company Sanofi. He subsequently joined the RCSI (Royal College of Surgeons in Ireland) in 1999 as a postdoctoral researcher under the supervision of Professor Kevin Nolan. In 2000, he established and has since led the Peptide Synthesis Laboratory at the RCSI, a national facility for the synthesis and modification of peptides. He was been appointed as a Lecturer in 2004, a Senior
Lecturer in 2008, and an Associate Professor of Chemistry in 2014. His research is focused on (cationic) antimicrobial peptides (AMPs), developing various derivatives tailored to different applications (eg., antibacterial, antibiofilm, anticancer), including the first targeted prodrugs and PEG-based peptidomimetics of AMPs to be reported. He is the National Representative for Ireland at the European Peptide Society Council (2018-2026) and a proud member of the SSPC since 2019 (https://sspc.ie/).
Research Keywords & Expertise
Peptidomimetics
antimicrobial peptides
prodrugs
Fingerprints
24%
antimicrobial peptides
15%
prodrugs
5%
Peptidomimetics
Short Biography
Marc Devocelle (https://www.rcsi.com/people/profile/mdevocelle) completed his PhD at the University of Lille (France) in the laboratory of Professor André Mortreux (homogeneous catalysis), under contract with the pharmaceutical company Sanofi. He subsequently joined the RCSI (Royal College of Surgeons in Ireland) in 1999 as a postdoctoral researcher under the supervision of Professor Kevin Nolan. In 2000, he established and has since led the Peptide Synthesis Laboratory at the RCSI, a national facility for the synthesis and modification of peptides. He was been appointed as a Lecturer in 2004, a Senior
Lecturer in 2008, and an Associate Professor of Chemistry in 2014. His research is focused on (cationic) antimicrobial peptides (AMPs), developing various derivatives tailored to different applications (eg., antibacterial, antibiofilm, anticancer), including the first targeted prodrugs and PEG-based peptidomimetics of AMPs to be reported. He is the National Representative for Ireland at the European Peptide Society Council (2018-2026) and a proud member of the SSPC since 2019 (https://sspc.ie/).
Well done!
